NO20080163L - Aminopyrimidiner som kinasemodulatorer - Google Patents

Aminopyrimidiner som kinasemodulatorer

Info

Publication number
NO20080163L
NO20080163L NO20080163A NO20080163A NO20080163L NO 20080163 L NO20080163 L NO 20080163L NO 20080163 A NO20080163 A NO 20080163A NO 20080163 A NO20080163 A NO 20080163A NO 20080163 L NO20080163 L NO 20080163L
Authority
NO
Norway
Prior art keywords
compounds
trkb
flt3
kit
aminopyrimidines
Prior art date
Application number
NO20080163A
Other languages
English (en)
Inventor
Michael David Gaul
Guozhang Xu
Christian Andrew Baumann
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20080163L publication Critical patent/NO20080163L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår aminopyrimidin forbindelser med Formel I: hvori R3, B, Z, Q, p, q og R1 er som definert heri, anvendelsen av slike forbindelser som protein tyrosin kinase modulatorer, særlig inhibitorer av FLT3 og/eller c-kit og/eller TrkB, anvendelsen av slike forbindelser for å redusere eller inhibere kinase aktivitet av FLT3 og/eller c-kit og/eller TrkB i en celle eller hos et subjekt, og anvendelsen av slike forbindelser for å hindre eller behandle en celleproliferativ forstyrrelse og/eller forstyrrelser relatert til FLT3 og/eller c-kit og/eller TrkB hos et subjekt. Foreliggende oppfinnelse angår videre fannasøytiske sammensetninger som innbefatter forbindelsene i følge oppfinnelsen og fremgangsmåter for behandling av tilstander slike som kreft og andre celle proliferative forstyrrelser.
NO20080163A 2005-06-10 2008-01-09 Aminopyrimidiner som kinasemodulatorer NO20080163L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16
PCT/US2006/022165 WO2006135644A1 (en) 2005-06-10 2006-06-07 Aminopyrimidines as kinase modulators

Publications (1)

Publication Number Publication Date
NO20080163L true NO20080163L (no) 2008-03-07

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080163A NO20080163L (no) 2005-06-10 2008-01-09 Aminopyrimidiner som kinasemodulatorer

Country Status (17)

Country Link
US (1) US20060281764A1 (no)
EP (1) EP1896029A1 (no)
JP (1) JP2008543760A (no)
KR (1) KR20080028911A (no)
AR (1) AR053895A1 (no)
AU (1) AU2006258054A1 (no)
BR (1) BRPI0611963A2 (no)
CA (1) CA2611470A1 (no)
EA (1) EA200800015A1 (no)
EC (1) ECSP077991A (no)
GT (1) GT200600248A (no)
IL (1) IL187693A0 (no)
NI (1) NI200700316A (no)
NO (1) NO20080163L (no)
PE (1) PE20070076A1 (no)
TW (1) TW200718693A (no)
WO (1) WO2006135644A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615880A2 (pt) * 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
BRPI0717035B8 (pt) 2006-09-08 2021-05-25 Hoffmann La Roche moduladores de benzotriazol cinase
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
WO2010054185A1 (en) * 2008-11-06 2010-05-14 Ambit Biosciences Corporation Phosphorylated fms-related tyrosine kinase 3 biomarker assay
JP2012508238A (ja) * 2008-11-07 2012-04-05 ハー・ルンドベック・アクチエゼルスカベット 生物活性を有するアミド
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP6959332B2 (ja) * 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
KR20190121404A (ko) * 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
US11608335B2 (en) 2018-02-12 2023-03-21 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
WO2022177974A1 (en) 2021-02-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
EP4553080A1 (en) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Also Published As

Publication number Publication date
PE20070076A1 (es) 2007-02-09
AU2006258054A1 (en) 2006-12-21
ECSP077991A (es) 2008-01-23
JP2008543760A (ja) 2008-12-04
IL187693A0 (en) 2008-08-07
NI200700316A (es) 2009-03-03
US20060281764A1 (en) 2006-12-14
TW200718693A (en) 2007-05-16
EP1896029A1 (en) 2008-03-12
AR053895A1 (es) 2007-05-23
CA2611470A1 (en) 2006-12-21
KR20080028911A (ko) 2008-04-02
WO2006135644A1 (en) 2006-12-21
BRPI0611963A2 (pt) 2010-10-13
GT200600248A (es) 2007-03-14
EA200800015A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
NO20080161L (no) Aminopyrimidiner som kinasemodulatorer
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20080174L (no) Alkylquinolin- og alkylquinazolinkinasemodulatorer
NO20080162L (no) Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20070506L (no) Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA201100966A1 (ru) Производные пиридазинона
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
ATE554087T1 (de) Neue kinaseinhibitoren
MX2010002004A (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
NO20090608L (no) Tyrosinkinaseinhibitorer
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
NO20080417L (no) Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE502935T1 (de) C-met-proteinkinasehemmer
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
ATE527264T1 (de) Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application